Para IV Winners and Losers - August 2018
This month’s Para IV developments suggest that there is likely to be benefit to Mylan Nv (MYL US) for Minivelle, Teva Pharmaceutical Sp Adr (TEVA...
366 Views
Para IV Winners and Losers - June 2018
This month’s Para IV developments suggest that there is likely to be benefit to Baxter International Inc (BAX US) on Premix Precedex (4mc/ml), Endo...
469 Views
Para IV Winners and Losers - April 2018
This month’s Para IV developments suggest that there is likely to be benefit to Cipla Ltd (CIPLA IN) on Xopenex HFA, Alvogen, Teva Pharmaceutical...
246 Views
Aussie Healthcare Daily: 1 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare & biotech companies as well as developments...
291 Views
Genomics as an Investment Theme
Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...
392 Views